Managers / Q4 2021 · view latest →
Mass General Brigham, Inc
CIK 0001678378 · 399 REVOLUTION DRIVE, SUITE 612, SOMERVILLE, MA, 02145 · 8572777268
Summary
Mass General Brigham, Inc reported $282M in U.S.-listed holdings across 7 positions for Q4 2021.
The portfolio is heavily concentrated: IVV alone accounts for 54.7% of reported value.
Compared with Q3 2021, the fund opened 4 new positions and exited 4.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 88.5% · $249M
- Common Stock · 11.5% · $33M
- ADR · 0.0% · $1,000
- Other · 0.0% · $1,000
Quarter-over-Quarter Changes full breakdown →
vs Q3 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ABNBAIRBNB INC | NEW | +5.2K | 5.2K | +$1,000 | $1,000 |
| DOCUSIGN INC | NEW | +3.9K | 3.9K | +$1,000 | $1,000 |
| DADA NEXUS LTD | NEW | +17.4K | 17.4K | +$1,000 | $1,000 |
| OYSTOYSTER PT PHARMA INC | NEW | +2.1K | 2.1K | +$1,000 | $1,000 |
| PDDPINDUODUO INC ADR | SOLD OUT | −44.2K | 0 | −$4M | $0 |
| XPEVXPENG INC | SOLD OUT | −38.4K | 0 | −$1M | $0 |
| NRIXNURIX THERAPEUTICS INC | SOLD OUT | −15.9K | 0 | −$476,000 | $0 |
| FULCFULCRUM THERAPEUTICS INC | SOLD OUT | −15.9K | 0 | −$447,000 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | IVVISHARES CORE SP 500 ETFhistory → | ETF | 54.68% | $154M | 323.3K |
| 2 | AGGISHARES CORE U.S. AGGREGATE ETFhistory → | ETF | 33.78% | $95M | 835.2K |
| 3 | COINCOINBASE GLOBAL INC CLASS Ahistory → | CL A | 11.54% | $33M | 128.9K |
| 4 | DOCUSIGN INC | COM | 0.00% | $1,000 | 3.9K |
| 5 | ABNBAIRBNB INC | CL A | 0.00% | $1,000 | 5.2K |
| 6 | OYSTOYSTER PT PHARMA INC | COM | 0.00% | $1,000 | 2.1K |
| 7 | DADA NEXUS LTD | ADS | 0.00% | $1,000 | 17.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $469M | 6 | May 5, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $810M | 7 | Jan 27, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $44M | 5 | Oct 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $21M | 4 | Jul 31, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $57M | 5 | Apr 4, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $28M | 2 | Jan 24, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $11M | 2 | Oct 23, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | Under review | 7 | Jul 21, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $128,310 | 6 | Apr 5, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 5 | Jan 19, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $192M | 3 | Oct 19, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $214M | 3 | Jul 27, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $235M | 5 | Apr 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $282M | 7 | Jan 19, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $371M | 7 | Oct 8, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $410M | 9 | Jul 19, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $639M | 3 | Apr 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $473M | 3 | Feb 8, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $126M | 2 | Oct 23, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $290M | 3 | Jan 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $436M | 3 | Oct 30, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $153M | 1 | Jul 29, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $162M | 1 | Apr 18, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $144M | 1 | Jan 30, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.